CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals (Nasdaq: CPIX) will release Q1 2026 financial results and provide a company update after market close on May 5, 2026.

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) will release Q1 2026 financial results and provide a company update after market close on May 5, 2026. A conference call is scheduled for May 5 at 4:30 p.m. ET, with registration, live dial‑in, a "Call Me" option, and a one‑year replay.

The company listed its FDA‑approved branded portfolio including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ and Talicia. Cumberland also noted ongoing Phase II programs for ifetroban in systemic sclerosis, Duchenne cardiomyopathy, and idiopathic pulmonary fibrosis.

Argus Apr 29 session

-1.64% close to close Open Argus

Details

News Market Reaction – CPIX

On Apr 29, the first trading day after this news, CPIX closed 1.64% below the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Market Context

This announcement sets the timing for Cumberland’s Q1 2026 results on May 5, 2026 and reiterates its...

Analysis

This announcement sets the timing for Cumberland’s Q1 2026 results on May 5, 2026 and reiterates its focus on hospital, gastroenterology and oncology products plus Phase II ifetroban programs. Historically, a prior earnings-date notice corresponded with a 4.59% move, indicating that scheduling updates have mattered to some investors. With recent corporate changes, including a planned sale of U.S. branded assets for $100 million, upcoming commentary and pipeline progress will be key metrics to watch.

Key Figures

Results date: May 5, 2026 Conference call time: 4:30 p.m. Eastern Time Replay duration: One year +1 more

Results date

May 5, 2026

Q1 2026 financial results release after market close

Conference call time

4:30 p.m. Eastern Time

Earnings call on May 5, 2026

Replay duration

One year

Earnings call replay availability via Investor Relations site

Ifetroban programs

Phase II

Systemic sclerosis, DMD cardiomyopathy, idiopathic pulmonary fibrosis

Previous Earnings date Reports

1 past event · Latest: Feb 24

Same Type 1 event

1. Feb 24

   Earnings date notice

   24h Move

   +4.6%

   Announced timing of 2025 annual results and update with investor call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

transdermal system, systemic sclerosis, duchenne muscular dystrophy, idiopathic pulmonary fibrosis, +1 more

5 terms

transdermal system medical

"Sancuso® (granisetron) transdermal system, for the prevention of nausea"

A transdermal system is a medical product, most often a patch, that releases a drug through the skin into the bloodstream over a set period so patients receive steady doses without pills or injections; think of it as a slow‑release sticker that delivers medicine through the skin. For investors it matters because device design, manufacturing, regulatory approval, patent protection and patient convenience all shape market size, recurring revenue and the risk of recalls or legal issues.

systemic sclerosis medical

"evaluating its ifetroban product candidate in patients with Systemic Sclerosis,"

Systemic sclerosis is a chronic autoimmune disease where the body's repair system overreacts, causing hardening and tightening of skin and internal organs much like scar tissue spreading beyond a wound. It matters to investors because it creates a clear medical need for new treatments, influences the size and urgency of clinical trials, and affects regulatory scrutiny, pricing power, and long-term healthcare costs tied to any therapy or diagnostic that proves effective.

duchenne muscular dystrophy medical

"cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

idiopathic pulmonary fibrosis medical

"Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.For more information"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

phase ii medical

"The Company also has a series of Phase II clinical programs underway"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026.

A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update.

The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a.

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/rik67g7q.

Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.

The company's portfolio of FDA-approved brands includes:

• Acetadote^® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
  
  
• Caldolor^® (ibuprofen) injection, for the treatment of pain and fever;
  
  
• Kristalose^® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
  
  
• Sancuso^® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
  
  
• Vaprisol^® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
  
  
• Vibativ^® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and
  
  
• Talicia^® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.

The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.

For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at www.cumberlandpharma.com.

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-q1-2026-financial-results--company-update-302756235.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cumberland Pharmaceuticals (CPIX) release Q1 2026 results and hold the conference call?

Cumberland will release Q1 2026 results after market close on May 5, 2026. According to the company, a conference call to discuss results and provide a company update is scheduled for May 5 at 4:30 p.m. ET.

How can investors register for the Cumberland (CPIX) May 5, 2026 conference call?

Investors can register via the provided online registration link before the call. According to the company, registrants receive a dial‑in and PIN or can use a "Call Me" option to be called at start time.

Will Cumberland (CPIX) provide a replay of the May 5, 2026 earnings call and where is it available?

Yes. According to the company, a replay will be available for one year on the company's Investor Relations webpage and at the specified media‑server replay URL after the call concludes.

Which FDA‑approved brands does Cumberland Pharmaceuticals (CPIX) list in its announcement?

The company lists branded products including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia. According to the company, these brands serve hospital acute care, gastroenterology, and oncology segments.

What clinical programs did Cumberland (CPIX) disclose in the Q1 2026 update?

Cumberland disclosed Phase II studies of the ifetroban candidate in systemic sclerosis, Duchenne cardiomyopathy, and idiopathic pulmonary fibrosis. According to the company, these programs are ongoing and at the Phase II stage.